NEW YORK (GenomeWeb News) – Protein Sciences has licensed its FluBiok recombinant influenza vaccine to Japanese biotech UMN Pharma to make and sell the product in that market.
Terms of the deal call for PSC to transfer technology to UMN, which will register, manufacture, market, and sell the vaccine in Japan for annual and pandemic use.